Nagayama Aiko, Vidula Neelima, Ellisen Leif, Bardia Aditya
Department of Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ther Adv Med Oncol. 2020 May 11;12:1758835920915980. doi: 10.1177/1758835920915980. eCollection 2020.
Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody-drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
三阴性乳腺癌（TNBC）是乳腺癌的一种异质性亚型，通常与侵袭性表型和不良预后相关。抗体药物偶联物（ADC）由通过连接子与细胞毒性药物连接的单克隆抗体组成，作为一种抗癌治疗方法正越来越受到关注。新型ADC药物如赛托珠单抗戈维汀（IMMU-132）和曲妥珠单抗德鲁昔康（DS-8201a）正处于转移性乳腺癌（包括TNBC）患者临床开发的后期阶段。在本文中，我们回顾并讨论了ADC在晚期TNBC患者中的开发及临床应用。
